[1. Z. Hlinak, J. Vinsova and E. Kasafirek, Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice, Eur. J. Pharmacol.314 (1996) 1–7.10.1016/S0014-2999(96)00485-2]Search in Google Scholar
[2. Z. Hlinak and I. Krejci, Oxiracetam pre-but not post-treatment prevented social recognition deficits produced with trimethyltin in rats, Behav. Brain Res.161 (2005) 213–219; DOI: 10.1016/j.bbr.2005.02.030.10.1016/j.bbr.2005.02.030]Search in Google Scholar
[3. C. Mondadori, B. Hengerer, T. Ducret and J. Borkowski, Delayed emergence of effects of memoryenhancing drugs: implications for the dynamics of long-term memory, Proc. Natl. Acad. Sci. USA91 (1994) 2041–2045.10.1073/pnas.91.6.2041]Search in Google Scholar
[4. C. Mondadori, H. J. Möbius and J. Borkowski, The GABAB receptor antagonist CGP 36,742 and the nootropic oxiracetam facilitate the formation of long-term memory, Behav. Brain Res. 77 (1996) 223–225.10.1016/0166-4328(95)00222-7]Search in Google Scholar
[5. W. H. Brooks, W. C. Guida and K. G. Daniel, The significance of chirality in drug design and development, Curr. Top. Med. Chem. 11 (2011) 760–770; DOI: 10.2174/156802611795165098.10.2174/156802611795165098]Search in Google Scholar
[6. A. J. Hutt, Chirality and pharmacokinetics: an area of neglected dimensionality, Drug Metabol. Drug Interact. 22 (2007) 79–112; DOI: 10.1515/DMDI.2007.22.2-3.79.10.1515/DMDI.2007.22.2-3.79]Search in Google Scholar
[7. T. Kolev, M. Spiteller and B. Koleva, Spectroscopic and structural elucidation of amino acid derivatives and small peptides: experimental and theoretical tools, Amino Acids38 (2010) 45–50; DOI: 10.1007/s00726-008-0220-9.10.1007/s00726-008-0220-9]Search in Google Scholar
[8. H. Lu, Stereoselectivity in drug metabolism, Expert Opin. Drug Metab. Toxicol. 3 (2007) 149–158; DOI: 10.1517/17425255.3.2.149.10.1517/17425255.3.2.149]Search in Google Scholar
[9. Q. Shen, L. Wang, H. Zhou, L. S. Yu and S. Zeng, Stereoselective binding of chiral drugs to plasma proteins, Acta Pharmacol. Sinica34 (2013) 998–1006; DOI: 10.1038/aps.2013.78.10.1038/aps.2013.78]Search in Google Scholar
[10. N. Inotsume and M. Nakano, Stereoselective determination and pharmaco-kinetics of dihydropyridines: an updated review, J. Biochem. Biophys. Methods54 (2002) 255–274; DOI: 10.1016/S0165-022X(02)00120-3.10.1016/S0165-022X(02)00120-3]Search in Google Scholar
[11. R. Mehvar and D. R. Brocks, Stereospecific pharmacokinetics and pharmacodynamics of betaadrenergic blockers in humans, J. Pharm. Pharm. Sci. 4 (2001) 185–200.]Search in Google Scholar
[12. L.A. Nguyen, H. He and C. Pham-Huy, Chiral drugs: an overview, Int. J. Biomed. Sci.2 (2006) 85–100.]Search in Google Scholar
[13. L. Chiodini, G. Pepeu, Composition Comprising S-oxiracetame for Use as Nootropic, EP. WO 1,993,006,826 A1, 15 April 1993; ref. Chem. Abstr. 119 (1993) 139083.]Search in Google Scholar
[14. W. S. Wang, H. Ji, H. T. Xie, M. Dai, Y. W. Jia, D. H. Liang, L. Ye and Z. Y. Rong, A sensitive and specific UPLC–MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in beagle dogs, Chin. J. Clin. Pharmacol Ther. 17 (2012) 988–994.]Search in Google Scholar
[15. J. B. Lecaillon, J. P. Dubois, H. Coppens, T. Darragon, W. Theobald, G. Reumond and H. Beck, Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with nongeriatric healthy subjects, Eur. J. Drug Metab. Pharmacokinet.15 (1990) 223–237.10.1007/BF031902082253653]Search in Google Scholar
[16. E. Perucca, A. Albrici, G. Gatti, R. Spalluto, M. Visconti and A. Crema, Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers, Eur. J. Drug Metab. Pharmacokinet. 9 (1984) 267–274.10.1007/BF031896506519128]Search in Google Scholar
[17. E. Perucca, J. Parini, A. Albrici, M. Visconti and E. Ferrero, Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly, Eur. J. Drug Metab. Pharmacokinet.12 (1987) 145148.]Search in Google Scholar
[18. X. Wan, H. Wang, P. Ma, L. Xi, J. Sun, Z. He, X. Zhang and X. Liu, Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC–MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration, J. Chromatogr. B. 969 (2014) 95–100; DOI: 10.1016/j.jchromb.2014.07.041.10.1016/j.jchromb.2014.07.04125168792]Search in Google Scholar